



XPHOZAH® Virtual Patent Marking

Ardelyx, Inc. is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. The following listing of patents serves notice of patent protection for **XPHOZAH®** (tenapanor hydrochloride) pursuant to patent marking provisions of various countries including the virtual patent marking provisions of the United States of America under 35 U.S.C. §287(a).

COUNTRY	PATENT NUMBER
United States of America	8,541,448
United States of America	8,969,377
United States of America	10,272,079
United States of America	10,940,146

29 April 2021